The Quality Unit must demonstrate robust oversight of commercial manufacturing, enforcing strict review and approval of validation protocols, batch records, and deviations. Effective CAPA implementation, thorough root cause analysis (RCA), and comprehensive material supplier qualification are highly scrutinized to ensure consistent biological product quality and a robust change management system aligned with ICH Q12 principles.

Facilities must be impeccably designed to prevent cross-contamination and microbial contamination, particularly when handling highly potent compounds or spore-forming microorganisms. Inspectors will rigorously scrutinize HVAC area classifications, clean utility loops (PW/WFI/Clean Steam), and equipment cleaning validation—placing heavy emphasis on strict adherence to clean/dirty hold times and adequate segregation protocols.

Commercial manufacturing operations must flawlessly mirror the exact processes defined in the BLA. This involves evaluating Stage 2 Process Performance Qualification (PPQ) execution, in-process sampling, and critical unit operations like master cell bank expansion, viral clearance/inactivation, UF/DF, and chromatography. Any unapproved reprocessing or deviations from validated parameters risk an immediate "Withhold" recommendation.

Data integrity is elevated to a primary, explicit audit objective (Objective 2). All computerized systems governing production and quality control testing must be fully validated (CSV) complying with 21 CFR Part 11, with rigorously enforced user access controls and independent audit trail reviews. Laboratory controls are thoroughly assessed for Out-Of-Specification (OOS) investigation adequacy, factual/contextual integrity, and the absence of unauthorized data manipulation.